细胞学标本PD-L1表达评估用于头颈鳞癌免疫治疗资格判定
本研究回顾性纳入21例头颈鳞状细胞癌(HNSCC)患者,配对组织学标本与含肿瘤细胞的细针穿刺(FNA)细胞块,用22C3克隆抗体染色并以CPS和TPS评分。细胞学与组织学CPS、TPS一致率均为76.2%(κ=0.607);以组织学为参照,CPS与TPS阳性预测值均为100%,CPS阴性预测值57.1%、TPS为50%。结论认为细胞块PD-L1 CPS评估可行,可在缺乏组织学标本时作为免疫治疗资格判定的替代。
要点
- 细胞块与组织学标本PD-L1 CPS、TPS一致率均为76.2%(κ=0.607)。
- 以组织学为参照,CPS与TPS阳性预测值均为100%。
- CPS阴性预测值57.1%、TPS为50%,阴性结果需谨慎解读。
核心结论
- HNSCC细胞学样本PD-L1表达与配对组织学样本高度一致。
- 细胞块PD-L1 CPS评估可行,可在无组织学标本时作为免疫治疗资格判定的替代。
研究设计与样本
- 回顾性研究,纳入21例已知组织学PD-L1状态的HNSCC患者及其配对含肿瘤细胞的FNA细胞块。
- 细胞块切片采用PD-L1抗体22C3克隆染色,所有病例以CPS和TPS评分。
主要发现
- 细胞学与组织学CPS一致率76.2%(κ=0.607),TPS一致率76.2%(κ=0.607)。
- 以组织学为参照标准,CPS与TPS的阳性预测值均为100%。
- 阴性预测值CPS为57.1%,TPS为50%。
关键数值与推荐
- CPS一致率76.2%,κ=0.607;TPS一致率76.2%,κ=0.607。
- 阳性预测值CPS与TPS均为100%;阴性预测值CPS 57.1%、TPS 50%。
临床怎么用
- 对以FNA淋巴结转移灶初诊的HNSCC患者,可用细胞块PD-L1 CPS评估辅助判断免疫治疗资格。
- 组织学标本不易获取时可考虑细胞块CPS作为替代,但阴性结果需结合临床谨慎解读。
局限性
- 回顾性设计,样本量仅21例。
- 原文未报告其他局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Immune checkpoint inhibitors targeting the programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) pathway have recently emerged as a frontline treatment for head and neck squamous cell carcinoma (HNSCC). The evaluation of PD-L1 expression by immunohistochemistry in histologic samples is used to determine the eligibility of patients with HNSCC for immunotherapy. Patients with newly diagnosed HNSCC are frequently diagnosed by fine-needle aspiration (FNA) of lymph nodes with metastatic disease. However, the evaluation of PD-L1 expression with the proposed combined positive score (CPS) has not been well established in cytology specimens. METHODS: This study retrospectively identified 21 HNSCC patients with a known PD-L1 status from histologic specimens and matched FNA specimens with tumor cells on cell blocks (CBs). The CB sections were stained with a PD-L1 antibody (22C3 clone). All cases were scored with CPS and the tumor proportion score (TPS). RESULTS: The data showed substantial concordance between cytologic and histologic specimens for CPS (agreement, 76.2%; κ = 0.607) and TPS (agreement, 76.2%; κ = 0.607). With histology used as a reference standard, the positive predictive value was 100% for both CPS and TPS, whereas the negative predictive value was 57.1% for CPS assessments and 50% for TPS assessments. CONCLUSIONS: PD-L1 expression in HNSCC cytology samples has high concordance with paired histologic samples. PD-L1 CPS evaluation is feasible in HNSCC cytology CBs and can act as a surrogate for determining eligibility for immunotherapy in cases in which a histologic specimen is not readily available.
引用
- Liu Z, Williams M, Stewart J, et al. Evaluation of programmed death ligand 1 expression in cytology to determine eligibility for immune checkpoint inhibitor therapy in patients with head and neck squamous cell carcinoma. Cancer Cytopathol. 2021. PMID: 34375025. doi:10.1002/cncy.22501
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。